Aardvark Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Aardvark Therapeutics, a clinical-stage biopharmaceutical company, is seeking to raise approximately $88.9 million through an initial public offering to advance its metabolic disease therapeutics.
NASDAQ
Aardvark Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to advance its novel therapeutics targeting metabolic diseases.